- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04314401
National Cancer Institute "Cancer Moonshot Biobank"
Cancer Moonshot Biobank Research Protocol
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Přehled studie
Postavení
Podmínky
- Maligní solidní novotvar
- Melanom
- Akutní myeloidní leukémie
- Mnohočetný myelom
- Anatomický karcinom prsu stadia III AJCC v8
- Anatomický karcinom prsu stadia IV AJCC v8
- Karcinom vejcovodů
- Karcinom žaludku
- Nemalobuněčný karcinom plic
- Fáze III rakoviny plic AJCC v8
- Fáze IV rakoviny plic AJCC v8
- Metastatický karcinom prostaty
- Karcinom vaječníků
- Karcinom jícnu
- Invazivní karcinom prsu
- Stádium IVB rakoviny prostaty AJCC v8
- Klinické stadium IV rakoviny žaludku AJCC v8
- Adenokarcinom gastroezofageální junkce AJCC v8
- Triple-negativní karcinom prsu
- Stádium IV Kolorektální karcinom AJCC v8
- Primární peritoneální karcinom
- Klinické stadium IV adenokarcinom jícnu AJCC v8
- Ovariální serózní adenokarcinom vysokého stupně
- Rakovina vejcovodů stadia III AJCC v8
- Etapa III rakoviny vaječníků AJCC v8
- Rakovina vejcovodu stadia IV AJCC v8
- Fáze IV rakoviny vaječníků AJCC v8
- Karcinom prsu s pozitivním hormonálním receptorem
- Malobuněčný karcinom plic
Detailní popis
PRIMARY OBJECTIVE:
I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.
SECONDARY OBJECTIVES:
I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.
II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.
III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.
IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.
V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.
VI. To provide residual biospecimens and associated data from the project to the cancer research community.
OUTLINE:
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní místa
-
-
-
San Juan, Portoriko, 00917
- San Juan Community Oncology Group
-
San Juan, Portoriko, 00927
- Centro Comprensivo de Cancer de UPR
-
San Juan, Portoriko, 00936
- San Juan City Hospital
-
-
-
-
Alabama
-
Daphne, Alabama, Spojené státy, 36526
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Spojené státy, 36532
- Thomas Hospital
-
Mobile, Alabama, Spojené státy, 36607
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Spojené státy, 36571
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Kingman, Arizona, Spojené státy, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Fort Smith, Arkansas, Spojené státy, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Arroyo Grande, California, Spojené státy, 93420
- PCR Oncology
-
Bakersfield, California, Spojené státy, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Loma Linda, California, Spojené státy, 92357
- Veterans Affairs Loma Linda Healthcare System
-
Salinas, California, Spojené státy, 93901
- Salinas Valley Memorial
-
-
Colorado
-
Brighton, Colorado, Spojené státy, 80601
- Intermountain Health Platte Valley Hospital
-
Denver, Colorado, Spojené státy, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Golden, Colorado, Spojené státy, 80401
- Lutheran Hospital - Cancer Centers of Colorado
-
Grand Junction, Colorado, Spojené státy, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Lafayette, Colorado, Spojené státy, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06102
- Hartford Hospital
-
-
Delaware
-
Dover, Delaware, Spojené státy, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, Spojené státy, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Boca Raton, Florida, Spojené státy, 33486
- Boca Raton Regional Hospital
-
Deerfield Beach, Florida, Spojené státy, 33064
- Broward Health North
-
Fort Lauderdale, Florida, Spojené státy, 33316
- Broward Health Medical Center
-
Tampa, Florida, Spojené státy, 33606
- Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30342
- Northside Hospital
-
Savannah, Georgia, Spojené státy, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Illinois
-
Bloomington, Illinois, Spojené státy, 61704
- Illinois CancerCare-Bloomington
-
Chicago, Illinois, Spojené státy, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Spojené státy, 60625
- Swedish Covenant Hospital
-
Danville, Illinois, Spojené státy, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Spojené státy, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Spojené státy, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, Spojené státy, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Spojené státy, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Spojené státy, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Spojené státy, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, Spojené státy, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Spojené státy, 62864
- SSM Health Good Samaritan
-
Pekin, Illinois, Spojené státy, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Spojené státy, 61615
- Illinois CancerCare-Peoria
-
Urbana, Illinois, Spojené státy, 61801
- Carle Cancer Center
-
Washington, Illinois, Spojené státy, 61571
- Illinois CancerCare - Washington
-
-
Iowa
-
Ames, Iowa, Spojené státy, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Spojené státy, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids, Iowa, Spojené státy, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, Spojené státy, 52402
- Physicians' Clinic of Iowa PC
-
Des Moines, Iowa, Spojené státy, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Spojené státy, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, Spojené státy, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Iowa City, Iowa, Spojené státy, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Spojené státy, 70808
- Our Lady of the Lake Physician Group
-
New Orleans, Louisiana, Spojené státy, 70118
- Children's Hospital New Orleans
-
New Orleans, Louisiana, Spojené státy, 70112
- University Medical Center New Orleans
-
Shreveport, Louisiana, Spojené státy, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, Spojené státy, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Spojené státy, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Spojené státy, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brunswick, Maine, Spojené státy, 04011
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Brunswick, Maine, Spojené státy, 04011
- Mid Coast Hospital
-
Damariscotta, Maine, Spojené státy, 04543
- MaineHealth LincolnHealth Hospital
-
Farmington, Maine, Spojené státy, 04938
- MaineHealth Franklin Hospital
-
Lewiston, Maine, Spojené státy, 04240
- Saint Mary's Regional Medical Center
-
Norway, Maine, Spojené státy, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, Spojené státy, 04102
- Maine Medical Partners Surgical Care
-
Portland, Maine, Spojené státy, 04102
- MMP Surgical Care Casco Bay
-
Portland, Maine, Spojené státy, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Spojené státy, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Spojené státy, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Spojené státy, 04074
- Maine Children's Cancer Program
-
Scarborough, Maine, Spojené státy, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Spojené státy, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
South Portland, Maine, Spojené státy, 04106
- MaineHealth Urology - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Spojené státy, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Spojené státy, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Spojené státy, 48118
- Chelsea Hospital
-
Grand Rapids, Michigan, Spojené státy, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Iron Mountain, Michigan, Spojené státy, 49801
- Dickinson County Healthcare System
-
Livonia, Michigan, Spojené státy, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Spojené státy, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
-
Missouri
-
Ballwin, Missouri, Spojené státy, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Joplin, Missouri, Spojené státy, 64804
- Freeman Health System
-
Joplin, Missouri, Spojené státy, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Spojené státy, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Spojené státy, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Spojené státy, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Spojené státy, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Spojené státy, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Spojené státy, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Spojené státy, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Spojené státy, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Spojené státy, 63128
- Mercy Hospital South
-
Washington, Missouri, Spojené státy, 63090
- Mercy Hospital Washington
-
-
Montana
-
Billings, Montana, Spojené státy, 59102
- Saint Vincent Frontier Cancer Center
-
Butte, Montana, Spojené státy, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Grand Island, Nebraska, Spojené státy, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
-
Nevada
-
Carson City, Nevada, Spojené státy, 89703
- Carson Tahoe Regional Medical Center
-
Las Vegas, Nevada, Spojené státy, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Spojené státy, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Spojené státy, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Spojené státy, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Spojené státy, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Spojené státy, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Spojené státy, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Hampshire
-
Nashua, New Hampshire, Spojené státy, 03060
- Saint Joseph Hospital
-
-
New Jersey
-
Morristown, New Jersey, Spojené státy, 07960
- Morristown Medical Center
-
Newton, New Jersey, Spojené státy, 07860
- Newton Medical Center
-
Pompton, New Jersey, Spojené státy, 07444
- Chilton Medical Center
-
Summit, New Jersey, Spojené státy, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Spojené státy, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
The Bronx, New York, Spojené státy, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Spojené státy, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, Spojené státy, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Spojené státy, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Spojené státy, 27834
- East Carolina University
-
Greenville, North Carolina, Spojené státy, 27834
- ECU Health Medical Center
-
Kernersville, North Carolina, Spojené státy, 27284
- Novant Health Cancer Institute - Kernersville
-
Kinston, North Carolina, Spojené státy, 28501
- ECU Health Oncology Kinston
-
Mount Airy, North Carolina, Spojené státy, 27030
- Novant Health Cancer Institute - Mount Airy
-
Pinehurst, North Carolina, Spojené státy, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Thomasville, North Carolina, Spojené státy, 27360
- Novant Health Cancer Institute - Thomasville
-
Washington, North Carolina, Spojené státy, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
Winston-Salem, North Carolina, Spojené státy, 27103
- Novant Health Forsyth Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73120
- Mercy Hospital Oklahoma City
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02908
- Roger Williams Medical Center
-
-
South Carolina
-
Columbia, South Carolina, Spojené státy, 29203
- Prisma Health Richland Hospital
-
Columbia, South Carolina, Spojené státy, 29220
- Prisma Health Baptist Hospital
-
Gaffney, South Carolina, Spojené státy, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Spojené státy, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Spojené státy, 29651
- Gibbs Cancer Center-Pelham
-
Spartanburg, South Carolina, Spojené státy, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Spojené státy, 29379
- SMC Center for Hematology Oncology Union
-
-
Texas
-
San Antonio, Texas, Spojené státy, 78229
- Audie L Murphy VA Hospital
-
-
Virginia
-
Lynchburg, Virginia, Spojené státy, 24501
- Centra Alan B Pearson Regional Cancer Center
-
Richmond, Virginia, Spojené státy, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Spojené státy, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton, Washington, Spojené státy, 98055
- Valley Medical Center
-
Yakima, Washington, Spojené státy, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Huntington, West Virginia, Spojené státy, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Spojené státy, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Eau Claire, Wisconsin, Spojené státy, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Spojené státy, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Spojené státy, 53215
- Aurora Saint Luke's Medical Center
-
Minocqua, Wisconsin, Spojené státy, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Spojené státy, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Spojené státy, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Spojené státy, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Spojené státy, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Patients undergoing treatment for cancer types with commercially available therapies.
Popis
Inclusion Criteria:
-
Is consistent with OR has been diagnosed with one of the following:
-
Colorectal cancer: stage IV
-
Non-small cell or small cell lung cancer: stage III/IV
-
Prostate cancer: metastatic prostate cancer
-
Gastric cancer, not otherwise specified (NOS): stage IV
-
Esophageal cancer, NOS: stage IV
-
Adenocarcinoma of gastroesophageal junction: stage IV
-
High grade serous ovarian cancer: stage III/IV
-
Invasive breast carcinoma: stage III/IV
-
Melanoma: stage III/IV
-
Acute myeloid leukemia
-
Multiple myeloma
-
For the purposes of this study,
- Re-staging is allowed
- Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
-
-
-
Patient should fit in one of the following four clinical scenarios (a-d)
- Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
- Scheduled to begin treatment with a new regimen of standard of care therapy OR
- Currently progressing on a regimen of standard of care therapy OR
- Currently being treated with a regimen standard of care therapy, without evidence of progression
-
Requirements for fresh tissue biospecimen collections at enrollment:
-
For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
-
For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
-
For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
-
For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
-
The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
- Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
-
-
-
Requirements for archival tissue:
-
For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
-
For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
-
Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:
- Contains the cancer type for which the participant is enrolled, and
- Was collected no more than 5 years prior to initiation of therapy, and
- Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
- Contains at least 10% tumor content. 70% tumor content is optimal, and
- No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
-
-
Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
- Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
- Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
-
Age 13 or older
-
Any sex
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
-
Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either
- Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
- African American with triple negative (ER-PR-HER2-)
-
NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)
Exclusion Criteria:
-
Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
- For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
-
Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
-
Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
-
Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
-
Factor X inhibitors are permitted
-
Use of anti-platelet drugs are permitted
- Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
-
-
NCI PDMR EXCLUSION CRITERIA: Patients with complete response
-
NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections
-
NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection
- Actively febrile patients with uncertain etiology of febrile episode
- All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
- No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
-
NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Observational (biospecimen collection, chart review)
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years. |
Undergo CT
Ostatní jména:
Undergo MRI
Ostatní jména:
Undergo PET/CT
Ostatní jména:
Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
Ostatní jména:
Medical charts are reviewed and data is collected
Ostatní jména:
Undergo paracentesis |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Procure, store and distribute longitudinal biospecimens and associated clinical data
Časové okno: Up to 10 years
|
Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate. |
Up to 10 years
|
|
Percentage of enrolled patients by cancer type and treatment regimen overall
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of minority and underserved study participants accrued
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of minority and underserved study participants accrued
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Pan-cancer gene panel tumor next generation sequencing test
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling is attempted
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling results are generated
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
Časové okno: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Lyndsay N Harris, National Cancer Institute (NCI)
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Onemocnění endokrinního systému
- Cévní onemocnění
- Kardiovaskulární choroby
- Genitální novotvary, muži
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Onemocnění pohlavních orgánů, muž
- Onemocnění prostaty
- Mužská urogenitální onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Střevní nemoci
- Onemocnění imunitního systému
- Nemoci dýchacích cest
- Novotvary podle histologického typu
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Nemoci trávicího systému
- Gastrointestinální onemocnění
- Onemocnění žaludku
- Střevní novotvary
- Rektální onemocnění
- Onemocnění pohlavních orgánů, ženy
- Plicní onemocnění
- Hematologická onemocnění
- Novotvary endokrinních žláz
- Novotvary hlavy a krku
- Novotvary dýchacího traktu
- Novotvary hrudníku
- Onemocnění tlustého střeva
- Nemoci jícnu
- Onemocnění vaječníků
- Adnexální onemocnění
- Genitální novotvary, ženy
- Gonadální poruchy
- Kožní choroby
- Nemoci prsu
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Neuroektodermální nádory
- Novotvary, zárodečné buňky a embryonální
- Novotvary, nervová tkáň
- Leukémie, myeloidní
- Karcinom, Bronchogenní
- Bronchiální novotvary
- Neuroendokrinní nádory
- Novotvary, plazmatické buňky
- Hemostatické poruchy
- Paraproteinémie
- Poruchy krevních bílkovin
- Hemoragické poruchy
- Leukémie
- Nevi a melanomy
- Novotvary kůže
- Onemocnění vejcovodů
- Novotvary prsu
- Onemocnění kůže a pojivové tkáně
- Hemická a lymfatická onemocnění
- Novotvary prostaty
- Novotvary žaludku
- Novotvary plic
- Kolorektální novotvary
- Leukémie, myeloidní, akutní
- Novotvary jícnu
- Novotvary vaječníků
- Karcinom, nemalobuněčné plíce
- Mnohočetný myelom
- Malobuněčný karcinom plic
- Melanom
- Trojité negativní novotvary prsu
- Novotvary vejcovodů
- Vyšetřovací techniky
- Terapeutika
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Vpichy
- Chirurgické postupy, operativní
- Techniky chemie, analytické
- Analýza spektra
- Drenáž
- Manipulace se vzorkem
- Magnetická rezonanční spektroskopie
- Paracentéza
Další identifikační čísla studie
- NCI-2020-00750
- NCI-2020-00750 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- 10323 (Jiný identifikátor: CTEP)
- 10323 (Jiný identifikátor: Division of Cancer Treatment and Diagnosis)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .